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ABSTRACT
Background
Experimental animal data show that protection against severe acute respiratory syndrome
coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is feasible. For an
effective immune prophylaxis in humans, broad coverage of different strains of SARS-CoV and
control of potential neutralization escape variants will be required. Combinations of virus-
neutralizing, noncompeting mAbs may have these properties.
Methods and Findings
Human mAb CR3014 has been shown to completely prevent lung pathology and abolish
pharyngeal shedding of SARS-CoV in infected ferrets. We generated in vitro SARS-CoV variants
escaping neutralization by CR3014, which all had a single P462L mutation in the glycoprotein
spike (S) of the escape virus. In vitro experiments confirmed that binding of CR3014 to a
recombinant S fragment (amino acid residues 318–510) harboring this mutation was abolished.
We therefore screened an antibody-phage library derived from blood of a convalescent SARS
patient for antibodies complementary to CR3014. A novel mAb, CR3022, was identified that
neutralized CR3014 escape viruses, did not compete with CR3014 for binding to recombinant
S1 fragments, and bound to S1 fragments derived from the civet cat SARS-CoV-like strain SZ3.
No escape variants could be generated with CR3022. The mixture of both mAbs showed
neutralization of SARS-CoV in a synergistic fashion by recognizing different epitopes on the
receptor-binding domain. Dose reduction indices of 4.5 and 20.5 were observed for CR3014
and CR3022, respectively, at 100% neutralization. Because enhancement of SARS-CoV infection
by subneutralizing antibody concentrations is of concern, we show here that anti-SARS-CoV
antibodies do not convert the abortive infection of primary human macrophages by SARS-CoV
into a productive one.
Conclusions
The combination of two noncompeting human mAbs CR3014 and CR3022 potentially
controls immune escape and extends the breadth of protection. At the same time, synergy
between CR3014 and CR3022 may allow for a lower total antibody dose to be administered for
passive immune prophylaxis of SARS-CoV infection.
The Editors’ Summary of this article follows the references.
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Severe acute respiratory syndrome (SARS) is caused by a
novel coronavirus (SARS-CoV) that spread in 2003 and 2004
from the Guangdong province of southern China to 32
countries in Asia, Europe, and North America, resulting in
over 8,000 cases and 774 deaths [1,2]. The main epidemic was
stopped in late 2003 through internationally coordinated
public health measures including early isolation of SARS
patients and quarantine of contacts, at considerable eco-
nomic costs to the affected countries [3–5]. In 2003 and 2004
a number of isolated SARS cases occurred again in China and
other Asian countries; some of these cases were linked to
laboratory or unknown exposure, but others were community
acquired and associated with exposure to the live game
animal restaurant trade in Guangdong province [6,7]. SARS-
CoV-like viruses almost identical to a patient’s isolate were
found in palm civet cats investigated during the same period
[7]. Phylogenetic analysis of approximately 100 SARS-CoV
isolates from humans and civet cats collected from 2002 to
2004 revealed that SARS is a zoonotic disease that is evolving
in palm civet and human hosts [7–9]. Furthermore, presum-
ably asymptomatic infection with SARS-CoV-like coronavi-
ruses has repeatedly occurred in wild animal handlers in
Guangdong province several years before the SARS epidemic
[9]. Recently, bats have been identiﬁed as an important
natural reservoir of the virus [10]. It is therefore unlikely that
the mass culling of civets cats performed in southern China is
sufﬁcient to prevent further spillover of SARS-CoV or SARS-
CoV-like viruses to the human population.
In the search for a vaccine against SARS, neutralizing
antibodies have been raised successfully in experimental
animals through immunization with whole killed virus or
recombinant vaccine constructs expressing the SARS-CoV
glycoprotein spike (S) [11–13]. Correspondingly, studies of
the immune responses in SARS patients have shown that the
appearance of neutralizing antibodies coincides with a
decrease of virus titers in serum, urine, stool, and nasophar-
yngeal secretions; in addition the beneﬁcial effect of
convalescent plasma in SARS patients has been reported
[14–16]. Neutralizing antibodies against SARS-CoV generated
through experimental vaccination or monoclonal antibody
(mAb) technology have repeatedly been shown in passive
transfer experiments to protect mice from infection by
reduction of viral replication [11,17–20]. In addition, the
human mAb CR3014, generated by phage display, completely
prevented lung pathology in the ferret model of SARS-CoV
infection and abolished shedding of the virus in pharyngeal
secretions [21]. CR3014 was shown to block interaction of the
S1 subunit of the S protein with its cellular receptor ACE2
[22].
Because passive immunization using polyclonal sera has
been reported to curb outbreaks of hepatitis A virus and to
prevent infection with varicella-zoster virus, mAb prophylaxis
may be an effective means of controlling a SARS outbreak
[23,24]. To this end, it is important that a mAb product offer
sufﬁcient breadth of protection against all relevant strains of
SARS-CoV and prevent the selection of neutralization escape
variants in the patient. In this study we therefore address
both of these issues and present the characteristics of a
combination of CR3014 with a new SARS-CoV neutralizing
human mAb that was isolated from a convalescent patient.
Because antibody-dependent enhancement of viral replica-
tion has been observed in macrophages for one member of
the coronavirus family (feline infectious peritonitis virus), we
also investigated whether a similar phenomenon occurs with
SARS-CoV [25]. Infection of primary human macrophages
with SARS-CoV has been reported to result in abortive
infection with no infectious virus progeny produced [26]. We
therefore studied whether virus infection in the presence of
serial dilutions of CR3014 or serum from a convalescent
SARS patient leads to productive virus infection.
Methods
Human Monoclonal Antibodies
The mAb CR3014 was isolated from a semisynthetic single-
chain variable antibody fragment (scFv) phage display library,
expressed as human IgG1 molecules and puriﬁed as described
previously [22,27]. An immune scFv phage display library was
constructed from lymphocytes of a convalescent SARS
patient from Singapore essentially as described [28]. From
this library, CR3022 scFv was selected for binding to UV-
inactivated SARS-CoV, essentially as described [22]. SARS-
CoV (Frankfurt 1 strain [FM1]) was prepared as described and
UV-irradiated for 15 min (UVB radiation, 280–350 nm; kmax,
306 nm) at 4 8C. CR3022 scFv was converted into a human
IgG1 format and expressed and puriﬁed as described. Anti-
rabies mAb CRJA served as negative control.
Virus Neutralization Assay and Determination of Antibody
Potency
Research involving SARS-CoV virus was performed under
biosafety level 3 containment. SARS-CoV strain HKU-39849
at 2 3 10
3 TCID50/ml in 100 ll was mixed with an equal
volume of serially diluted mAb in maintenance medium (MM,
MEM supplemented with 1% v/v FCS) and incubated for 1 h
at 37 8C. Subsequently, the mixture was inoculated in
octuplicate onto 96-well plate containing a 80% conﬂuent
culture of fetal rhesus kidney cells (FRhK-4; American Type
Culture Collection, Manassas, Virginia, United States; #CRL-
1688). The FRhK-4 cells were cultured at 37 8C and observed
after 3–4 d for the development of CPE. The mAb
concentrations required for 50% and 100% neutralization
were calculated from two-fold dilution series according to the
Spearman-Karber formula. To quantitatively compare the
neutralizing potency of a CR3014/CR3022 combination with
the individual potencies of the mAbs, they were mixed in an
equimolar ratio and the 100% and 50% neutralization
potency of a serial dilution of the mix was determined. The
concepts of the combination index (CI) and dose reduction
index (DRI) were used to quantify synergistic effects as
described previously [29,30].
Generation and Characterization of Neutralization Escape
Variants
Serial dilutions ranging from 10
 1 to 10
 8 of SARS-CoV
strain HKU-39849 were incubated in the presence of a
constant amount of CR3014 (20 lg/ml) or CR3022 (60 lg/ml),
for 1 h at 37 8C and 5% CO2 before addition to wells
containing FRhK-4 cells. The virus-mAb mixture was in-
cubated with cells for 1 h at 37 8C and 5% CO2, then the virus
was removed and the cells were washed twice with medium.
Finally, cells were incubated for 2 d in the presence of the
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natant of cells incubated with highest virus dilution showing
CPE, containing the potential escape viruses, was harvested
and stored at 4 8C until further use. Virus samples were
freeze-thawed once, serial dilutions were prepared in
medium and added to wells containing FRhK-4 cells, and
the dilutions incubated for 1 h at 37 8C and 5% CO2 in the
presence of mAb. Wells were then overlaid with agarose
containing mAbs at the above concentration and incubated
for 3–5 d at 37 8C and 5% CO2. Individual escape virus
plaques were picked using a Pasteur pipette and freeze-
thawed once, and the escape viruses were ampliﬁed on FRhK-
4 cells. To identify possible mutations in the SARS-CoV spike
protein of each of the escape viruses, the nucleotide sequence
of the SARS-CoV S open reading frame (ORF) was deter-
mined. Viral RNA of each of the escape viruses and wild-type
SARS-CoV virus was isolated and converted into cDNA by
standard RT-PCR. Subsequently, the cDNA was used for
nucleotide sequencing of the SARS-CoV S ORF in order to
identify mutations. Secondly, the neutralization index was
determined for each of the escape viruses. Therefore, each
escape virus and wild-type SARS-CoV (100 TCID50) was
incubated for 1 h at 37 8C and 5% CO2 with mAb at the above
concentration before addition to FRhK-4 cells. The virus was
allowed to attach to the cells for 1 h at 37 8C and 5% CO2,
after which the inoculum was removed and cells were washed
twice with medium before being replenished with medium
containing mAb. After a 2 d incubation at 37 8C and 5% CO2
the medium was harvested and the TCID50/ml of each virus
was determined. The neutralization index was determined by
subtracting the number of infectious virus particles (ex-
pressed as log TCID50/ml) produced in FRhK-4 cell cultures
infected with virus in the presence of mAb from the number
of infectious virus particles (log TCID50/ml) produced in
FRhK-4 cell cultures infected with virus alone. An index lower
than 2.5 was considered evidence of escape.
Recombinant SARS-CoV Glycoprotein Spike Fragments
The generation of the plasmids encoding recombinant
spike (S) fragments comprising residues 318–510 of the
human SARS-CoV strains FM1, GZ02, Sin3408, Shanghai
LY, GZ-C, Sino1–11, BJ302 clone 2, GD03T0013, GD01, and
the palm civet cat derived strain SZ3 (AY304486), as well as
expression and puriﬁcation of the recombinant proteins have
previously been described [22].
Epitope Mapping using ELISA
DirectELISAusingtherecombinantlyexpressed Sfragment
comprising amino acids 318–510 (S318–510) was performed
with the mAbs as described [22]. Competition ELISA was
performed as follows. Anti-Myc-captured S318–510 fragment
of the Frankfurt 1 strain was incubated with nonsaturating
amounts of biotinylated IgG in the presence or absence of
competing IgG. Bound biotinylated IgG was detected with
streptavidin-conjugated-HRP (BD Pharmingen, San Diego,
California, United States). Alternatively, S318–510 was cap-
tured by CR3014 or CR3022, detected using a biotinylated
CR3014 and CR3022, and developed as described above.
BIAcore Analysis
Surface plasmon resonance analyses were performed at 25
8C on a BIAcore3000 (Biacore AB, Uppsala, Sweden). CM5
sensorchips and running buffer HBS-EP were from Biacore
AB. Recombinant S318–510 was immobilized to CM5 chips
using an amine coupling procedure resulting in a response
level of approximately 1,000 resonance units. Kinetic analysis
was performed to determine the association rate constant
(ka), dissociation rate constant (kd), and the afﬁnity (KD) of the
mAbs. Therefore, a concentration series of 0.4–250 nM IgG
was prepared using two-fold dilutions in HBS-EP. Samples
were injected in duplicate at a ﬂow rate of 30 ll/min
(injection time, 2 min; dissociation time, 5 min). The sensor
chip surface was regenerated with a 5 ll pulse of 5 mM NaOH.
Biacore evaluation software (BIAevaluation, version 3.2) was
used to ﬁt the association and dissociation curves of all
concentrations injected.
Immune Enhancement Assay of SARS-CoV Replication in
Primary Human Macrophages
Preparation of primary human monocytes/macrophages
a n dt h e i ri n f e c t i o nw i t hS A R S - C o Vw a sp e r f o r m e da s
previously described [26]. To investigate the effect of
subneutralizing doses of anti-SARS Abs on viral infection in
macrophages, 300 ll of serially diluted mAb in MM medium,
convalescent serum from a SARS-CoV exposed individual, or
serum from a healthy individual was mixed with 300 llo f
SARS-CoV. MM medium mixed with SARS-CoV served as the
virus control. The virus/mAb mixtures and virus/serum
mixtures were incubated for 1 h at 37 8C. Then, 250 llo f
the mixtures was added to duplicate wells containing macro-
phages. After 1 h of virus adsorption at 37 8C, the virus
inoculum was removed, infected cells were washed with
macrophage SFM culture medium and incubated in macro-
phage SFM medium supplemented with 0.6 lg/ml penicillin
and 60 lg/ml streptomycin. Samples of the culture super-
natants were collected at days 0, 1, 2, 3, 5, and 7 postinfection
and stored at  70 8C for virus titration experiments. SARS-
CoV was titrated and the TCID50 determined essentially as
described. RNA was isolated from infected macrophages at 6
and 24 hours postinfection using the RNeasy Mini kit
(Qiagen, Valencia, California, United States) according to
the manufacturer’s instructions. Quantiﬁcation of positive-
and negative-strand viral RNA was performed by real-time
quantitative RT-PCR targeting the ORF1b gene, as described
previously [31]. The SARS-CoV RNA levels were normalized
for the levels of b-actin mRNA.
Results
All CR3014 Neutralization Escape Variants of SARS-CoV
Display a P462L Mutation in the Spike Glycoprotein
Full neutralization curves of wild-type SARS-CoV and one
CR3014-neutralization escape virus with CR3014 and CR3022
are shown in Figure 1. All ﬁve neutralization escape variants
were completely refractory to neutralization with CR3014.
Sequencing of the complete spike gene of these variants
isolated from two separate viral cultures (n¼5) revealed that
all carried a single point mutation at amino acid position 462
(proline to leucine, P462L), which abolished binding of
CR3014 to the recombinantly expressed receptor-binding
domain (RBD) fragment (S318–510) displaying this mutation
(Figure 2). This mutation has to date been observed neither in
SARS-CoV isolates from human patients nor in SARS-CoV-
like coronaviruses found in civet cats. In two independent
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of up to 60 lg/ml CR3022 did not result in the generation of
neutralization escape variants (unpublished data).
Human mAb CR3022 Neutralizes CR3014 Escape Variants
of SARS-CoV by Binding Noncompetitively to the RBD of
the Spike Glycoprotein
An antibody phage display library was constructed from
RNA isolated from the lymphocytes of a convalescent SARS
patient originating from Singapore. Antibody CR3022 was
isolated which completely neutralized the SARS-CoV strain
HKU-39849 and the CR3014 escape variants at a concen-
tration of 23.5 lg/ml (Table 1). CR022 was shown in ELISA to
bind noncompetitively with CR3014 to the recombinantly
expressed RBD of the S glycoprotein of wild-type SARS-CoV
(strain Frankfurt 1) and also to the mutated RBD (P462L) of
the escape variants (Figures 2 and 3), which were completely
neutralized by 16 lg/ml of this mAb. In contrast to CR3014,
CR3022 did not prevent binding of a recombinant S fragment
composed of amino acids 1–565 to Vero cells (unpublished
data). The sequences of the variable regions of the heavy and
light chains of CR3022 were deposited at GenBank.
CR3022 Shows Extended Reactivity with Recombinantly
Expressed S Fragments of Different SARS-CoV Strains
In addition to the fragments recognized by CR3014,
CR3022 also binds to the RBDs of SARS-CoV-like isolate
SZ3 isolated from a civet cat and from a human SARS-CoV
with a mutation of asparagine to serine at amino acid 479
(N479S), which were not or only partially recognized by
CR3014, respectively (Figure 4).
CR3014 and CR3022 Neutralize SARS-CoV Synergistically
To evaluate whether CR3014 and CR3022 would neutralize
SARS-CoV in an additive or synergistic manner, we used the
classic method of titrating the neutralizing potency of an
equimolar mixture of the antibodies and comparing the dose
response with that from neutralization assays performed with
the individual antibodies (Figure 1). The data were analyzed
by applying the median effect principle as formulated by
Chou and Talalay [29]. A combination index (CI) of less than
1, indicating synergistic neutralization, was observed in three
independent experiments for both 50% and 100% neutral-
ization of wild-type SARS-CoV (Table 1). As is evident from
the DRIs, the mixture of antibodies reduced the required
antibody dose especially for CR3022 considerably (DRI ¼
20.4). Interestingly, CR3014 also slightly enhanced neutraliza-
tion of the escape viruses by CR3022 (Figure 1).
Simultaneous Binding of mAbs CR3014 and CR3022 to
Recombinant S318–510 Fragment Does Not Change Their
Affinities
To investigate changes of afﬁnities as a possible mechanism
of synergy, the KD for CR3014 and CR3022 binding
sequentially or simultaneously to recombinant RBD was
investigated. The individual KD values for CR3014 and
CR3022 were 16.3 nM and 0.125 nM, respectively; for the
antibodies binding simultaneously was 5.71 nM; and for
binding of CR3014 to CR3022-saturated S318–510 was 14.8
nM. Compared to the dose reduction indices of 4.5 and 20.5
for CR3014 and CR3022, respectively, neither simultaneous
nor sequential binding of the mAbs resulted in changes of KD
Table 1. Synergy of CR3014 and CR3022 for SARS-CoV
Neutralization and Coverage of CR3014 Escape Viruses by
CR3022
Virus Calculation Single mAb or Combination (lg/ml)
CR3014 CR3022 CR3014
þ CR3022
Wild-type
SARS-CoV
100% neutralization
a 5.2 23.5 1.1 þ 1.1
50% neutralization
a 2.0 11.0 0.5 þ 0.5
CI100 —
b —
b 0.27
c
CI50 —
b —
b 0.34
c
Mean DRI100
d 4.5 20.5 —
b
Mean DRI50
d 3.7 20.5 —
b
CR3014 escape
virus (E6)
100% neutralization
a —
e 16 5.2
50% neutralization
a —
e 6.3 3.6
aAll assays performed in octuplicate. Data are also shown in Figure 1.
bNot applicable.
cSynergy is indicated when CI , 1.
dDRIs were measured by comparing the doses required to reach a given degree of virus
neutralization when the antibodies were used alone and in combination.
eAt 50 lg/ml CR3014 no neutralization was observed.
DOI: 10.1371/journal.pmed.0030237.t001
Figure 1. Neutralization of Wild-Type SARS-CoV and a CR3014-
Neutralization Escape Variant (E6) with mAbs CR3014 and CR3022
Individually and in Combination
Neutralization of 100 TCID50 of each virus was performed in octuplicate.
Data are also shown in Table 1.
DOI: 10.1371/journal.pmed.0030237.g001
Figure 2. Binding of mAbs CR3014 and CR3022 to Recombinant Wild-
Type and P462L-Substituted S318–510 Fragments Analyzed by ELISA
Bars represent the means 6 standard deviation.
DOI: 10.1371/journal.pmed.0030237.g002
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through cooperative binding.
SARS-CoV Does Not Replicate in Human Macrophages in
the Presence of mAb CR3014 or Convalescent Serum
SARS-CoV did not replicate to measurable titers after day
2 on macrophages in the absence or presence of serial
dilutions of mAb CR3014, a control mAb, or serum from a
convalescent patient (unpublished data). Figure 5 shows the
detection of SARS-CoV positive (P) or negative (N) strand
RNA (replication intermediate) by RT-PCR in the same assay.
Positive-strand RNA is detectable at 6 and 24 h postinfection,
indicating uptake of virus by the macrophage. In the presence
of 2.8310
 5 to 2.8310
 3 lg/ml of CR3014 a slight increase in
virus uptake into macrophages is suggested by the increased
copy number of positive-strand RNA (Figure 5). In contrast,
negative-strand RNA, which indicates viral replication, is
detectable at much lower levels that are constant over time,
with no difference between the virus incubated with CR3014
or control antibody. Taken together, these results show that
with or without monoclonal or polyclonal antibody, macro-
phages take up SARS-CoV, but this uptake does not lead to
the productive virus replication and release of infectious
virus.
Discussion
Our results show that SARS-CoV can be neutralized
synergistically by human mAbs targeting the receptor-bind-
ing domain of the virus. The combination of two mAbs
expanded the breadth of protection and controlled potential
immune escape variants while reducing the total antibody
concentration required to neutralize the virus. In view of the
proven efﬁcacy of passive prophylaxis of SARS-CoV infection
in animal models using single mAbs, our data provide a
rationale to develop cocktails of mAbs for human SARS
prophylaxis.
Although the SARS epidemic of 2003 was successfully
contained, the risk of its re-emergence remains from its
natural animal reservoir, from intermediate hosts such as
civet cats in live animal markets, or from laboratory
associated infections. The re-emergence and community
spread of SARS in Beijing in February 2004 required the
quarantine of large numbers of contacts; the social and
economic consequences of such measures are considerable.
The availability of prophylactic and therapeutic measures
against SARS-CoV would greatly assist the control of any
Figure 3. Competition ELISA on Immobilized S318–510
Binding of biotinylated CR3014 (A) and CR3022 (B) was analyzed in the
presence of competitor CR3014 (open circles), CR3022 (closed circles),
and control mAb (open squares). Binding is expressed as percentage of
binding without competitor.
DOI: 10.1371/journal.pmed.0030237.g003
Figure 4. Binding of Human mAbs to S318–510 Fragments in ELISA
Wild-type and variant fragments were synthesized according to published sequences of SARS-CoV strains. Wild-type S318–510 from strain Frankfurt 1,
variant fragments from strains GZ02 (K344R), Sin3408 (S353F), Shanghai LY (R426G and N437D), GZ-C (Y436H), Sino1–11 (Y442S), BJ302 cl. 2 (N479S),
SZ3 (K344R, F360S, N479K, and T487S), GD03T0013 (K344R, F360S, L472P, D480G, and T487S), and GD01 (K344R and F501Y). Bars represent the means
6 standard deviation.
DOI: 10.1371/journal.pmed.0030237.g004
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therefore remains a high priority [32].
With respect to vaccine development, considerable pro-
gress has been made in understanding the immune response
against the virus and deﬁning correlates of protection.
Patients with high viral loads and shedding of SARS-CoV in
pharyngeal secretions have elevated mortality [33]. Corre-
spondingly, the development of neutralizing antibody titers
correlates with a decrease of virus titers in serum, urine, stool,
and nasopharyngeal secretions [15]. Progress has also been
made in understanding the target of the neutralizing immune
response through immunization with whole killed SARS-CoV
and recombinant vectors expressing the S glycoprotein and
other structural proteins [11–13]. Neutralizing antibodies
seem to be predominantly directed against a domain of the
S1 subunit of the spike protein, deﬁned by amino acids 318–
510, which is responsible for interaction of the virus with its
cellular receptor ACE2 [34–37]. Mapping of this RBD using a
panel of mouse mAbs has led to the identiﬁcation of six
distinct neutralizing epitopes, which are all conformation-
dependent [38]. The neutralizing potency of the mAb
correlated directly with their ability to block the RBD-ACE2
interaction in recombinant assays; however, several neutral-
izing mAbs were also identiﬁed that bind to two distinct
epitopes of the RBD without inhibiting the interaction with
ACE2.
The concept of using polyclonal or monoclonal antibodies
with neutralizing activity against SARS-CoV for passive
immunization to control both development of severe disease
and transmission from human to human of the virus is based
on several observations. The use of convalescent serum in
SARS patients was reported to be associated with possible
beneﬁt and in any event was not associated with adverse
effects [14,16]. In consequence, commercial production of
SARS antiserum from human donors has been initiated in
China [39]. Passive transfer of immune serum generated
through immunization of animals with whole killed virus or
vector-expressed full-length S or S fragments has reduced
viral replication in a mouse model of SARS-CoV infection
[11,18]. Human mAbs have been generated through phage
display, immortalization of human B-cells from SARS-
patients, or immunization of transgenic mice, and were
shown to display protective efﬁcacy in the mouse model
[17,19,20]. In addition, the human mAb CR3014 reduced
SARS-CoV replication in the lungs of infected ferrets,
completely prevented the development of lung lesions, and
abolished viral shedding in the pharyngeal secretions of the
animals [21]. Because SARS-CoV is spread by the respiratory
and the fecal-oral route, the observation that passive
immunization is successful in controlling outbreaks of
hepatitis A virus and protecting against varicella-zoster and
respiratory syncytial virus infection argues for the feasibility
of an emergency immune prophylaxis during a SARS
outbreak [23,24,40].
Monoclonal antibody prophylaxis against SARS must meet
certain criteria to be effective. The breadth of protection of a
single mAb may not be sufﬁcient to protect against all
clinically relevant strains of the virus, and it has been
Figure 5. Infection of Differentiated Human Macrophages with SARS-CoV (HKU-39849) in the Presence of CR3014 or a Control mAb
One representative experiment of three independent experiments is shown. Total RNA was extracted at 6 and 24 hours postinfection, and the copy
number of positive (P) and negative (N) strand RNA of SARS-CoV ORF1b was determined by real-time quantitative RT-PCR and normalized for the levels
of b-actin mRNA. The bars represent mean of duplicate viral load titrations. In the control experiment, * indicates an aberrant result.
DOI: 10.1371/journal.pmed.0030237.g005
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outbreak may be required to select for optimally neutralizing
mAbs [19]. A comprehensive analysis of the variability of
approximately 100 full-length genomes of SARS-CoV isolates
obtained from human patients and civet cats between 2002
and 2004 revealed that the S glycoprotein, especially the RBD,
is under strong positive selective pressure during the
transition from animal-to-animal to human-to-human trans-
mission, because of differences in the ACE2 receptors of civet
cats and humans [7]. The highest variability of the RBD is
observed within the group of SARS-CoV-like viruses isolated
from animals, with no data as yet available concerning the
receptor speciﬁcity of the newly discovered bat-CoV [10].
Interestingly, patients infected with SARS-CoV-like viruses
had a milder course of disease and did not transmit the
viruses to other persons, presumably because of insufﬁcient
adaptation of the civet cat virus RBD to human ACE2, which
is required for productive infection of human cell lines
[19,41,42]. The RBD of SARS-CoV isolates from the next
SARS epidemic will therefore likely be very similar to the
isolates from 2003. The RBD of human SARS-CoV isolates is
highly conserved and alignment of 114 sequences published
in GenBank revealed only eight different S sequences not
identical to the FM1 strain [22]. Of all human isolates SARS-
CoV-like isolate GD03T0013, which was obtained from a
patient in 2003, shows the highest RBD divergence and closest
relatedness to civet cat strains [7]. Human mAb CR3014 binds
well to recombinantly expressed RBDs representing seven of
the RBD variants, including GD03T0013, but less to a variant
with a N479S mutation found in human isolate BJ302 cl.2, and
not at all to an RBD derived from the civet cat SARS-CoV-like
isolate SZ3. Antibody CR3022, derived by phage display from
a convalescent SARS patient, binds well to the latter two
variants in addition to the others. A combination of CR3014
and CR3022 may therefore offer sufﬁcient protection not
only against SARS-CoV strains but also against SARS-CoV-
like viruses originating from civet cats.
Viral replication in the presence of a mAb, especially at
subneutralizing concentrations, carries the risk of selecting
neutralization escape variants. We therefore analyzed escape
variants of SARS-CoV strain HKU-39849 generated under
selective pressure of CR3014 or CR3022, which was un-
successful for the latter. All CR3014 escape variants had the
same single amino acid exchange in the RBD (P462L), which
has not been reported in any SARS-CoV or SARS-CoV-like
virus to date. This variant was successfully neutralized with
CR3022, extending the breadth of protection of this antibody
combination from naturally occurring variants also to
possible CR3014 immune escapes. A similar strategy was
previously pursued to develop a mAb product for postexpo-
sure prophylaxis of rabies [43]. Because neutralization escape
in vitro may not accurately reﬂect the in vivo situation, the
CR3014/CR3022 combination needs to be tested at subneutr-
alizing concentrations in animal models of SARS-CoV
infection.
Further investigation of the CR3014/CR3022 combination
revealed that the antibodies neutralize wild-type SARS-CoV
synergistically in vitro, with DRIs of about four and 20 for the
two mAbs, respectively. Synergism of neutralizing mAbs has
not yet been reported for SARS-CoV, but was observed for
combinations of two, three, or four mAbs directed against
different epitopes on the HIV-1 envelope glycoprotein,
leading to a two- to ten-fold increase of neutralization titers
[30,44,45]. Mechanistically, cooperative binding of mAbs may
induce conformational changes in the antigen thereby
altering afﬁnities (allosteric effect), lead to intermolecular
interaction of bivalent antibodies, or result in interaction of
the Fc regions of antibodies brought into close contact [46].
As determined by ELISA, CR3014 and CR3022 bind simulta-
neously to the RBD of the S1 subunit of the glycoprotein S of
SARS-CoV. However, measuring separate, sequential, and
simultaneous binding of the mAbs in Biacore did not reveal
enhanced afﬁnity of the antibody mixture over the individual
afﬁnities, especially for CR3022. Another possible explan-
ation for synergism could be increased breadth of protection
against different quasispecies of a viral isolate [30]. Hetero-
geneous sequences have been detected through direct
sequencing of SARS-CoV RNA recovered from single patient
samples, and adaptive mutations induced by repeated cell
culture passage have been reported [47–49]. It should there-
fore be formally investigated whether SARS-CoV quasispecies
formation in cell culture may inﬂuence the outcome of virus
neutralization assays. Lastly, CR3022 could interfere with
binding of the S1 subunit to a known or unknown coreceptor
of the virus [50]. The mechanism by which the two mAbs
neutralize SARS-CoV synergistically therefore remains pres-
ently elusive.
It was previously shown that CR3014 protects ferrets from
challenge with SARS-CoV at a dose of 10 mg/kg by completely
preventing lung pathology and abolishing shedding of the
virus [21]. This antibody dose compares well with the
required dosage of Palivizumab (15 mg/kg), which protects
at-risk infants from infection with respiratory syncytial virus
and is currently the only licensed antiviral monoclonal
antibody [40]. However, the required amount of CR3014 for
protecting a standard 70 kg adult is relatively high, and it
would be desirable to use a lower dose for economic reasons.
Furthermore, the even lower potency of CR3022 precludes its
use as a stand-alone prophylaxis. Therefore, the observed
four- to twenty-fold dose reduction of the individual mAbs in
the CR3014/CR3022 mixture may hold an attractive option to
reduce the total antibody dose required for neutralizing the
virus in vivo while at the same time expanding the breadth of
protection.
In this study, we also addressed the potential problem of
antibody-dependent enhancement (ADE), which is a well-
recognized phenomenon observed in infections with another
coronavirus, feline infectious peritonitis virus. Both immu-
nization and passive transfer of antibody was shown to
mediate this phenomenon and mAbs have been used to map
neutralizing and enhancing epitopes on the spike glycopro-
tein of feline infectious peritonitis virus [25,51]. There is no
direct evidence of ADE linked to SARS-CoV infection in
humans to date, and infection of human macrophages with
SARS-CoV was previously shown to be abortive [25]. How-
ever, it was recently shown, in a viral pseudotype assay
expressing the full-length spike glycoproteins of SARS-CoV-
like viruses, that these cannot be neutralized with either
homologous or heterologous mouse immune sera, and that
both the sera and human mAbs neutralizing SARS-CoV
enhance infectivity of the pseudotype for the human
adenocarcinoma cells used as indicator system [34]. Given
that ADE in feline infectious peritonitis virus infection is
mediated by increased macrophage uptake of virus in the
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macrophage infectivity assays in the presence of CR3014 and
human convalescent serum. In this type of assay, ADE of
Dengue and Ross River virus infection has previously been
demonstrated [52]. The addition of varying concentrations of
CR3014 or convalescent SARS serum to SARS CoV did not
convert the abortive infection into a productive one,
reducing the likelihood that ADE will be observed in vivo
after passive immunization.
In conclusion, we propose that a combination of neutraliz-
ing mAbs targeting the RBD of SARS-CoV has the potential
to control SARS-CoV infection with a high level of efﬁcacy
and safety, and possibly at reduced economic cost. Isolation
of suspected SARS cases and quarantine of exposed contacts
have proved effective in controlling epidemics. However, the
direct and indirect costs involved in quarantine measures are
very substantial [4]. Monoclonal antibody prophylaxis (ring
vaccination) in case of a SARS outbreak may prove more cost
effective.
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Editors’ Summary
Background. Late in 2002, severe acute respiratory syndrome (SARS)
emerged in the Guangdong province of China. In February 2003, an
infected doctor from the province carried this new viral threat to human
health to Hong Kong. Here, people staying in the same hotel caught the
disease and took it to other countries. SARS was on the move, hitching
lifts with international travellers. Because the virus responsible for
SARS—SARS-CoV—spread by close person-to-person contact and killed
10% of the people it infected, health experts feared a world-wide
epidemic. This was avoided by the World Health Organization issuing a
global alert and warning against unnecessary travel to affected areas and
by public-health officials isolating patients and their close contacts. By
July 2003, the first SARS epidemic was over. 8,098 people had been
infected; 774 people had died. Since then, sporadic cases of SARS have
been contained locally.
Why Was This Study Done? The first epidemic of SARS was caused by
an animal virus that became adapted to spread between people. There is
no reason this process won’t be repeated. If it is, stringent quarantine
measures could again prevent a global epidemic, but at considerable
economic cost. What is needed is a way to prevent SARS developing in
healthy people who have been exposed to SARS-CoV and to treat sick
people so that they are less infectious and can fight the virus. In this
study, researchers have been investigating ‘‘passive immunization’’ as a
way to limit SARS epidemics. In passive immunization, short-term
protection against illness is achieved by injecting antibodies—proteins
that recognize specific molecules (called antigens) on foreign organisms
such as bacteria and viruses and prevent those organisms from causing
disease. Antibodies for passive immunization can be isolated from blood
taken from people who have had SARS, or they can be manufactured as
so-called ‘‘human monoclonal antibodies’’ in a laboratory. One of these
human monoclonal antibodies—CR3014—had been previously made
and shown to prevent lung damage in ferrets infected with SARS-CoV
and to stop the infected animals from infecting others. But for effective
disease prevention in people, a single monoclonal antibody might not be
enough. There are strains of SARS-CoV that CR3014 does not recognize
and therefore cannot act against. Also, the virus can alter the antigen
recognized by CR3014 when it is grown at a low antibody concentration,
producing so-called escape variants; if this happens CR3014 can no
longer prevent these escape variants from killing human cells.
What Did the Researchers Do and Find? The researchers tested how
well a combination of two monoclonal antibodies controlled SARS-CoV
killing of human cells. First, they showed that CR3014 escape variants all
had the same small change in a part of the virus surface that interacts
with human cells. CR3014 blocked this interaction in the parent SARS-
CoV strain but not in the escape variants. They then made a new
monoclonal antibody—CR3022—that prevented both the parent SARS-
CoV stain and the CR3014 escape viruses from killing human cells. The
two antibodies bound to neighboring parts of the virus surface, and both
of them could bind at the same time. CR3022 also bound to surfaces of
SARS-CoV strains to which CR3014 does not bind. And when they tried,
the researchers could not generate any viral escape variants to which
CR3022 was unable to bind. Finally, the effect of the two antibodies
together on inhibition of SARS-CoV killing of human cells was more than
the sum of their individual effects.
What Do These Findings Mean? A combination of two (or more) human
monoclonal antibodies that recognize different parts of the SARS-CoV
surface that interacts with human cells might be a good way to
immunize people passively against SARS-CoV. It might minimize the
possibility of escape variants arising, broaden the range of virus strains
against which protection is provided, and reduce the amount of antibody
needed for effective protection. Before the approach is tried in people, it
will have to be tested in animals—results from experiments done on
human cells in dishes are not always replicated in whole animals or
people. If the approach passes further tests, the hope is that passive
immunization of people with SARS and their close contacts might reduce
disease severity in infected people and reduce viral spread as effectively
as dramatic quarantine measures
Additional Information. Please access these websites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030237.
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